Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07FGA
|
|||
| Former ID |
DIB008839
|
|||
| Drug Name |
ZYC101a
|
|||
| Indication | Cervical cancer [ICD-11: 2C77.0; ICD-9: 180] | Phase 2/3 | [1] | |
| Company |
MGI Pharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00264732) A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.